Karuna Therapeutics Inc
Change company Symbol lookup
Select an option...
KRTX Karuna Therapeutics Inc
SNSE Sensei Biotherapeutics Inc
ALGS Aligos Therapeutics Inc
SRRA Sierra Oncology Inc
ATOS Atossa Therapeutics Inc
OSMT Osmotica Pharmaceuticals PLC
SAND Sandstorm Gold Ltd
GRVI Grove Inc
STON Stonemor Inc
TK Teekay Corp
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Karuna Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on to create and deliver transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate, KarXT, is an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. It is initially developing KarXT, for the treatment of acute psychosis in patients with schizophrenia. The Company is developing a pipeline of therapeutic programs to address symptoms associated with schizophrenia and psychosis associated with Alzheimer’s disease (AD), as well as various forms of pain. KarXT is a combination of xanomeline and trospium. KarXT combines xanomeline, a muscarinic agonist, with trospium, a muscarinic antagonist, to stimulate muscarinic receptors in the CNS. It is advancing a pipeline of therapeutic programs to address the positive, negative and cognitive symptoms.

Price
Delayed
$123.87
Day's Change
-0.74 (-0.59%)
Bid
--
Ask
--
B/A Size
--
Day's High
125.49
Day's Low
121.22
Volume
(Light)

Today's volume of 27,849 shares is on pace to be much lighter than KRTX's 10-day average volume of 191,081 shares.

27,849

Goldman Sachs powers past Wall Street forecast, stock rises

11:44 am ET October 15, 2021 (MarketWatch)
Print

Steve Gelsi

Investment bank sees 'increased likelihood' of monetary policy tightening in near term

Goldman Sachs Group Inc. on Friday said its third-quarter earnings vaulted more than 60% with a big boost from its investment banking unit as the Dow component benefited from brisk capital raising and other deal-making on Wall Street.

In another bright spot, the bank's global markets revenue turned in a particularly strong beat of analyst projections, and the banks assets under management set a fresh record.

The bank also forecast an "increased likelihood" of monetary policy tightening in the near term due to inflationary pressures. Any rate hikes are seen as beneficial to lenders that have seen their loan margins pressured by low interest rates.

CEO David Solomon said the firm "saw strong operating performance" and that its "opportunity set continues to be attractive across all of our businesses."

Goldman Sachs (GS) shares rose 2.6% in midday trades, enough to be the top performer among the Dow Jones Industrial Average's components.

CFRA analyst Kenneth Leon reiterated a strong buy rating on Goldman Sachs and raised his 12-month price target to $470 a share from $445 a share. "Best-in-class, GS is executing on all cylinders with industry leading performance and gaining market share and growing assets under supervision," he said. "And yet, GS trades at significant 2022 discount to S&P 500 or lead asset managers like Schwab (SCHW) and BlackRock (BLK)."

The Wall Street giant said its net income rose to $5.28 billion, or $14.93 a share, from $3.23 billion, or $8.98 a share, in the year-ago period.

Net revenue increased to $13.6 billion from $10.8 billion. Net interest income climbed to $1.56 billion from $1.08 billion.

Goldman Sachs soundly beat the consensus analyst estimates for earnings of $10.14 a share and revenue of $11.72 billion, according to a survey by FactSet.

Goldman's investment banking unit nearly doubled its revenue to $3.55 billion from $1.93 billion, and ahead of the analyst estimate of $2.6 billion.

The firm's global markets revenue increased to $5.61 billion from $4.55 billion. The latest figure blew past the FactSet estimate of $3.70 billion.

During the third quarter, Goldman Sachs repurchased $1.0 billion of stock. Its headcount at the end of the third-quarter was 43,000, up 5.4% from the end of the second quarter.

Its third-quarter provision for credit losses of $175 million compared with $278 million a year ago.

Assets under supervision increased $67 billion during the quarter to $2.37 trillion, a record. Firmwide management and other fees of $1.95 billion also set a record.

Turning to M&A, Goldman acquired two businesses in the quarter: NN Investment Partners and GreenSky Inc. Both deals are expected to close by the end of the first quarter.

Goldman Sachs shares are up 48.3% so far this year, compared with an increase of 18.2% by the S&P 500 and a rise of 38% by the KBW Bank Index .

-Steve Gelsi

	

(END) Dow Jones Newswires

October 15, 2021 11:44 ET (15:44 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.